2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors Massad, L. Stewart; Einstein, Mark H.; Huh, Warner K.; More Massad, L. Stewart; Einstein, Mark H.; Huh, Warner K.; Katki, Hormuzd A.; Kinney, Walter K.; Schiffman, Mark; Solomon, Diane; Wentzensen, Nicolas; Lawson, Herschel W.; for the 2012 ASCCP Consensus Guidelines Conference Less Journal of Lower Genital Tract Disease. 17:S1-S27, April 2013. Abstract Abstract In Brief In Brief Favorites PDF Get Content & Permissions In Brief: Updated guidelines describe consensus management for abnormal cervical cancer screening tests and cancer precursors, accommodating new epidemiologic concepts and screening guidelines. Buy Erratum
Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; More Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; Fetterman, Barbara; Poitras, Nancy E.; Lorey, Thomas; Cheung, Li C.; Raine-Bennett, Tina; Gage, Julia C.; Kinney, Walter K. Less Journal of Lower Genital Tract Disease. 17:S28-S35, April 2013. Abstract Abstract In Brief In Brief Favorites PDF Get Content & Permissions In Brief: The principles of “benchmarking” and “equal management of equal risk” are introduced to guide safe and consistent incorporation of human papillomavirus and Pap cotesting into cervical screening and management. Buy
Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; More Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; Fetterman, Barbara; Poitras, Nancy E.; Lorey, Thomas; Cheung, Li C.; Raine-Bennett, Tina; Gage, Julia C.; Kinney, Walter K. Less Journal of Lower Genital Tract Disease. 17:S36-S42, April 2013. Abstract Abstract In Brief In Brief Favorites PDF Get Content & Permissions In Brief: Women testing HPV-negative/ASCUS have a similar risk for CIN 3+ or cancer as women testing Pap-negative alone but have a higher risk than women testing HPV-negative/Pap-negative. Buy
Five-Year Risks of CIN 2+ and CIN 3+ Among Women With HPV-Positive and HPV-Negative LSIL Pap Results Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; More Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; Fetterman, Barbara; Poitras, Nancy E.; Lorey, Thomas; Cheung, Li C.; Raine-Bennett, Tina; Gage, Julia C.; Kinney, Walter K. Less Journal of Lower Genital Tract Disease. 17:S43-S49, April 2013. Abstract Abstract In Brief In Brief Favorites PDF Get Content & Permissions In Brief: Because women with HPV-negative/LSIL cotest results have low risk for CIN 3+, they might be better managed by being retested in 6 to 12 months rather than referred for immediate colposcopy. Buy
Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV-Positive and HPV-Negative High-Grade Pap Results Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; More Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; Fetterman, Barbara; Poitras, Nancy E.; Lorey, Thomas; Cheung, Li C.; Raine-Bennett, Tina; Gage, Julia C.; Kinney, Walter K. Less Journal of Lower Genital Tract Disease. 17:S50-S55, April 2013. Abstract Abstract In Brief In Brief Favorites PDF Get Content & Permissions In Brief: All women with AGC, ASC-H, or HSIL had high risks for cancer, even women testing HPV-negative, supporting referring all of them for immediate colposcopy. Buy
Five-Year Risks of CIN 3+ and Cervical Cancer Among WomenWho Test Pap-Negative But Are HPV-Positive Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; More Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; Fetterman, Barbara; Poitras, Nancy E.; Lorey, Thomas; Cheung, Li C.; Raine-Bennett, Tina; Gage, Julia C.; Kinney, Walter K. Less Journal of Lower Genital Tract Disease. 17:S56-S63, April 2013. Abstract Abstract In Brief In Brief Favorites PDF Get Content & Permissions In Brief: Women with negative cytology who tested HPV-positive had low enough CIN 3+ risk to return in 1 year for cotesting, when half of women remained HPV-positive and would be referred for colposcopy. Buy
Five-Year Risk of CIN 3+ to Guide the Management of Women Aged 21 to 24 Years Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; More Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; Fetterman, Barbara; Poitras, Nancy E.; Lorey, Thomas; Cheung, Li C.; Raine-Bennett, Tina; Gage, Julia C.; Kinney, Walter K. Less Journal of Lower Genital Tract Disease. 17:S64-S68, April 2013. Abstract Abstract In Brief In Brief Favorites PDF Get Content & Permissions In Brief: The finding of extremely low risk for cancer and low risk for CIN 3 among women aged 21 to 24 years supports conservative management of abnormal screening results in this age group. Buy
Follow-up Testing After Colposcopy: Five-Year Risk of CIN 2+ After a Colposcopic Diagnosis of CIN 1 or Less Katki, Hormuzd A.; Gage, Julia C.; Schiffman, Mark; More Katki, Hormuzd A.; Gage, Julia C.; Schiffman, Mark; Castle, Philip E.; Fetterman, Barbara; Poitras, Nancy E.; Lorey, Thomas; Cheung, Li C.; Raine-Bennett, Tina; Kinney, Walter K. Less Journal of Lower Genital Tract Disease. 17:S69-S77, April 2013. Abstract Abstract In Brief In Brief Favorites PDF Get Content & Permissions In Brief: For women with CIN 1/negative colposcopy and antecedent HPV-positive/ASC-US or LSIL, a single negative postcolposcopy cotest reduced the risk to a level consistent with a 3-year return. Buy
Five-Year Risk of Recurrence After Treatment of CIN 2, CIN 3, or AIS: Performance of HPV and Pap Cotesting in Posttreatment Management Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; More Katki, Hormuzd A.; Schiffman, Mark; Castle, Philip E.; Fetterman, Barbara; Poitras, Nancy E.; Lorey, Thomas; Cheung, Li C.; Raine-Bennett, Tina; Gage, Julia C.; Kinney, Walter K. Less Journal of Lower Genital Tract Disease. 17:S78-S84, April 2013. Abstract Abstract In Brief In Brief Favorites PDF Get Content & Permissions In Brief: Negative cotests after treatment seemed to provide more reassurance against recurrent CIN 2+ than either negative Pap tests or HPV tests alone. Buy
